From different backgrounds and lifestyles, Elle, Jennifer, Tony, and Sean discuss their first-hand experiences with IgA nephropathy and the associated challenges of living with this rare disease.
Dana V. Rizk, MD, professor of medicine, University of Alabama at Birmingham; and Gerald Appel, MD, professor of medicine and co-director of the Center for Glomerular Disease, Columbia…
Obi Umeh, MD, MSc, VP, Franchise Global Program Leader at Takeda, discusses interim results from a study investigating mezagitamab for the treatment of patients with IgA nephropathy. This…
Dana Rizk, MD, professor of medicine at the University of Alabama at Birmingham, discusses the approval of Fabhalta (iptacopan) for adults with IgA nephropathy. Iptacopan, a Factor B…
Dana V. Rizk, MD, professor of medicine, University of Alabama at Birmingham; and Gerald Appel, MD, professor of medicine and co-director of the Center for Glomerular Disease, Columbia…
Obi Umeh, MD, MSc, VP, Franchise Global Program Leader at Takeda, discusses interim results from a study investigating mezagitamab for the treatment of patients with IgA nephropathy. This…
Dana Rizk, MD, professor of medicine at the University of Alabama at Birmingham, discusses the approval of Fabhalta (iptacopan) for adults with IgA nephropathy. Iptacopan, a Factor B…
Anand Reddy, MRCP (UK), FACP, FASN, Permian Regional Medical Center, Andrews, Texas; and Richard Lafayette, MD, FASN, professor of medicine and director of the Stanford Glomerular Disease Center,…
From different backgrounds and lifestyles, Elle, Jennifer, Tony, and Sean discuss their first-hand experiences with IgA nephropathy and the associated challenges of living with this rare disease.
Sean Converse was diagnosed with IgA nephropathy in late 2022 following an acute upper respiratory illness. Sean discusses challenges and his experience with IgA nephropathy.
